Danske Bank’s TG Therapeutics TGTX Stock Holding History

Danske Bank’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-700	Closed	-$20.9K	–	1547
2025 Q4	$20.9K	Hold	700	–	–	﹤0.01%	1187
2025 Q3	$25.3K	Hold	700	–	–	﹤0.01%	1124
2025 Q2	$25.2K	Buy	700 +500	+250%	+$18.6K	﹤0.01%	1144
2025 Q1	$7.89K	Hold	200	–	–	﹤0.01%	1117
2024 Q4	$6.02K	Sell	200 -600	-75%	-$17.2K	﹤0.01%	1183
2024 Q3	$18.7K	Sell	800 -7,072	-90%	-$154K	﹤0.01%	1340
2024 Q2	$140K	Hold	7,872	–	–	﹤0.01%	926
2024 Q1	$120K	Buy	+7,872	New	+$125K	﹤0.01%	968

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Danske Bank's TGTX Position: Q1 2026 in Review

Danske Bank sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 700 shares — an estimated $20.9K sold.

Danske Bank first reported a position in TGTX in Q1 2024 and held it in 8 quarters. The position peaked at $140K in Q2 2024. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Danske Bank reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Danske Bank sold 700 TG Therapeutics shares in Q1 2026, an estimated $20.9K.
Danske Bank first reported a position in TG Therapeutics in Q1 2024 and held it in 8 quarters.
Danske Bank's TG Therapeutics position peaked at $140K in Q2 2024.
364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.